Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20085466 | 0.84 | TRPA1 (0.40) | LPLLIPGGSK3AGSK3BTRPA1 | |
| SCHEMBL31620771 | 0.84 | TRPA1 (0.40) | LPLLIPGGSK3AGSK3BTRPA1 | |
| SCHEMBL16722737 | 0.82 | NOS1 (0.39) | LPLLIPGGSK3AGSK3BFFAR1 | |
| SCHEMBL29502769 | 0.82 | TRPA1 (0.42) | LPLLIPGGSK3AGSK3BTRPA1 | |
| SCHEMBL20088492 | 0.82 | TRPA1 (0.42) | LPLLIPGGSK3AGSK3BTRPA1 | |
| SCHEMBL24147853 | 0.80 | LPL (0.35) | LPLLIPGGSK3AGSK3BTRPA1 | |
| SCHEMBL30483068 | 0.80 | LPL (0.35) | LPLLIPGGSK3AGSK3BTRPA1 | |
| SCHEMBL24147798 | 0.79 | LRRK2 (0.33) | LPLLIPGGSK3AGSK3BLRRK2 | |
| SCHEMBL30483028 | 0.79 | LRRK2 (0.33) | LPLLIPGGSK3AGSK3BLRRK2 | |
| SCHEMBL16728595 | 0.77 | LPL (0.37) | LPLLIPGGSK3AGSK3BROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022133037-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-11312705-B2 | Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-04-26 | — | — | US | disclosed |
| US-11312705-B2 | Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-04-26 | — | — | US | disclosed |
| CN-109963854-B | Heteroaryl [4,3-c ] pyrimidine-5-amine derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-109890823-B | Fused azaheterocyclic compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20210032224-A1 | HETEROARYL[4,3-C]PYRIMIDINE-5-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
| EP-3532476-B1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-19 | — | — | EP | disclosed |
| EP-3575301-A1 | HETEROARYL[4,3-C]PYRIMIDINE-5-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-12-04 | — | — | EP | disclosed |
| US-10155769-B2 | Fused azaheterocyclic compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-18 | — | — | US | disclosed |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155769-B2 | Fused azaheterocyclic compounds and their use as AMPA receptor modulators | GRIN3A, GRIN1, GRIN2B | LPL 4152/4885LIPG 2805/4885GSK3A 3895/4885 |
| US-11312705-B2 | Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof | ADORA2A, ADORA1, ADORA3 | LPL 2729/4885LIPG 2740/4885GSK3A 1633/4885 |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN3A, GRIN1, GRIN2B | LPL 4152/4885LIPG 2805/4885GSK3A 3895/4885 |
| US-20210032224-A1 | HETEROARYL[4,3-C]PYRIMIDINE-5-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | TBXA2R, ADORA1, ADORA2A | LPL 2040/4885LIPG 1725/4885GSK3A 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.